Qi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qi Wang has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Hong Zhu
Key Laboratory for Advanced Materials and Joint International Research Laboratory of Precision Chemistry and Molecular Engineering Shanghai Key Laboratory of Functional Materials Chemistry Feringa Nobel Prize Scientist Joint Research Center Institute of Fine Chemicals Frontiers Science Center for Materiobiology and Dynamic Chemistry School of Chemistry and Molecular Engineering East China University of Science and Technology Shanghai China
20 shared publications Zhirong Zhu
Key Laboratory for Advanced Materials and Joint International Research Laboratory of Precision Chemistry and Molecular Engineering, Shanghai Key Laboratory of Functional Materials Chemistry, Frontiers Science Center for Materiobiology and Dynamic Chemistry, Institute of Fine Chemicals, School of Chemistry and Molecular Engineering
14 shared publicationsTing Yang
7 shared publicationsXiaolei Zhao
7 shared publicationsZhenxing Liu
7 shared publicationsShanshan Hu
Key Laboratory for Advanced Materials and Joint International Research Laboratory of Precision Chemistry and Molecular Engineering, Shanghai Key Laboratory of Functional Materials Chemistry, Feringa Nobel Prize Scientist Joint Research Center, Institute of Fine Chemicals, Frontiers Science Center for Materiobiology and Dynamic Chemistry, School of Chemistry and Molecular Engineering
6 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by KEAI Publishing in Green Chemical Engineering
- Vol. 7 (4) , 363-369
Detection of tumor immunity-related ENPP1 using AIE-active probe QM-AMP
- 1 December 2026
- Published by KEAI Publishing in Green Chemical Engineering
- Vol. 7 (4) , 363-369
Open AccessDetection of tumor immunity-related ENPP1 using AIE-active probe QM-AMP
- Open Access
- 22 October 2026
- Published by Wiley in Advanced Science
- p. e78405
Spatiotemporally Precise Rheumatoid Arthritis Therapy via a Triple‐Locked Cascaded Nanoplatform With Dual‐Channel Self‐Reporting
Achieving precise spatiotemporal control over combination therapies in rheumatoid arthritis (RA) remains heavily compromised by conventional nanoplatforms, which typically suffer from premature off‐target leakage, coupled drug release, and inadequate in vivo tracking capabilities. Herein, a programmable orthogonally branched triple‐locked nanotheranostic platform (MB@YW NPs) is engineered to seamlessly synchronize spatial localization, chemically orthogonal multidrug liberation, and real‐time multichannel self‐reporting. The system comprises a pH‐responsive polymeric matrix co‐encapsulating a HOCl‐activatable methotrexate prodrug (MB‐MTX) and an ONOO − /light‐responsive sulfasalazine prodrug (YW‐SSZ). Precluding systemic leakage, synovial acidity dictates initial spatial targeting by triggering tissue‐specific disassembly and subsequent macrophage internalization. Subsequently, non‐interfering pathophysiological triggers exclusively liberate distinct therapeutics through independent pathways: intracellular HOCl purely unlocks methotrexate with concomitant near‐infrared “turn‐on” fluorescence, whereas an isolated ONOO − /light sequence locally activates sulfasalazine accompanied by a blue “on‐to‐off” readout. This lack of cross‐talk successfully discriminates multiplexed activation states. In vivo, this triple‐locked platform efficiently alleviates oxidative stress and remodels the inflammatory microenvironment, leading to markedly suppressed joint destruction in collagen‐induced arthritis models. Furthermore, transcriptomic analysis reveals these synergistic macroscopic benefits are driven by targeted modulation of the cAMP/NF‐κB signaling axis. Collectively, this work establishes a transformative and generalizable framework for independently coordinated, next‐generation precision multi‐prodrug nanomedicine.
- 22 October 2026
- Published by Wiley in Advanced Science
- p. e78405
Open AccessSpatiotemporally Precise Rheumatoid Arthritis Therapy via a Triple‐Locked Cascaded Nanoplatform With Dual‐Channel Self‐Reporting
Achieving precise spatiotemporal control over combination therapies in rheumatoid arthritis (RA) remains heavily compromised by conventional nanoplatforms, which typically suffer from premature off‐target leakage, coupled drug release, and inadequate in vivo tracking capabilities. Herein, a programmable orthogonally branched triple‐locked nanotheranostic platform (MB@YW NPs) is engineered to seamlessly synchronize spatial localization, chemically orthogonal multidrug liberation, and real‐time multichannel self‐reporting. The system comprises a pH‐responsive polymeric matrix co‐encapsulating a HOCl‐activatable methotrexate prodrug (MB‐MTX) and an ONOO − /light‐responsive sulfasalazine prodrug (YW‐SSZ). Precluding systemic leakage, synovial acidity dictates initial spatial targeting by triggering tissue‐specific disassembly and subsequent macrophage internalization. Subsequently, non‐interfering pathophysiological triggers exclusively liberate distinct therapeutics through independent pathways: intracellular HOCl purely unlocks methotrexate with concomitant near‐infrared “turn‐on” fluorescence, whereas an isolated ONOO − /light sequence locally activates sulfasalazine accompanied by a blue “on‐to‐off” readout. This lack of cross‐talk successfully discriminates multiplexed activation states. In vivo, this triple‐locked platform efficiently alleviates oxidative stress and remodels the inflammatory microenvironment, leading to markedly suppressed joint destruction in collagen‐induced arthritis models. Furthermore, transcriptomic analysis reveals these synergistic macroscopic benefits are driven by targeted modulation of the cAMP/NF‐κB signaling axis. Collectively, this work establishes a transformative and generalizable framework for independently coordinated, next‐generation precision multi‐prodrug nanomedicine.
- Open Access
- 7 September 2026
- Published by Wiley in Smart Molecules
- p. e70102
pKa engineering of a near‐infrared fluorescent probe for sensitive imaging of oxidative stress in atherosclerotic plaques
Reactive oxygen species (ROS) are key mediators in the progression of atherosclerosis, making ROS imaging valuable for evaluating oxidative stress in plaques. However, most activatable fluorescent probes show limited fluorescence enhancement under physiological conditions because their fluorophores are insufficiently ionized at neutral pH, resulting in weak signal output and low sensitivity. To address this issue, we developed a pKa‐engineering strategy by introducing electron‐withdrawing fluorine atoms at the ortho‐positions of the phenolic hydroxyl group to construct the fluorophore DCM‐2F‐OH. The difluoro substitution lowered the pKa to 6.0, enabling complete ionization and strong near‐infrared fluorescence emission at physiological pH. Incorporation of a boronate ester trigger further afforded the activatable ROS probe DCM‐2F‐B. DCM‐2F‐B displayed a 12.8‐fold fluorescence turn‐on response toward ROS, significantly higher than that of the non‐fluorinated analog (2.5‐fold), along with a low detection limit (0.03 μM) and low cytotoxicity. The probe successfully visualized endogenous ROS in lipopolysaccharide (LPS)‐stimulated macrophages and detected elevated ROS levels in aortic valve tissues from apolipoprotein E knockout (ApoE −/− ) mice, consistent with histopathological analysis. This work demonstrates that pKa engineering is an effective strategy for improving activatable fluorescent probes under physiological conditions and provides a useful tool for imaging oxidative stress in cardiovascular diseases.
- 7 September 2026
- Published by Wiley in Smart Molecules
- p. e70102
Open AccesspKa engineering of a near‐infrared fluorescent probe for sensitive imaging of oxidative stress in atherosclerotic plaques
Reactive oxygen species (ROS) are key mediators in the progression of atherosclerosis, making ROS imaging valuable for evaluating oxidative stress in plaques. However, most activatable fluorescent probes show limited fluorescence enhancement under physiological conditions because their fluorophores are insufficiently ionized at neutral pH, resulting in weak signal output and low sensitivity. To address this issue, we developed a pKa‐engineering strategy by introducing electron‐withdrawing fluorine atoms at the ortho‐positions of the phenolic hydroxyl group to construct the fluorophore DCM‐2F‐OH. The difluoro substitution lowered the pKa to 6.0, enabling complete ionization and strong near‐infrared fluorescence emission at physiological pH. Incorporation of a boronate ester trigger further afforded the activatable ROS probe DCM‐2F‐B. DCM‐2F‐B displayed a 12.8‐fold fluorescence turn‐on response toward ROS, significantly higher than that of the non‐fluorinated analog (2.5‐fold), along with a low detection limit (0.03 μM) and low cytotoxicity. The probe successfully visualized endogenous ROS in lipopolysaccharide (LPS)‐stimulated macrophages and detected elevated ROS levels in aortic valve tissues from apolipoprotein E knockout (ApoE −/− ) mice, consistent with histopathological analysis. This work demonstrates that pKa engineering is an effective strategy for improving activatable fluorescent probes under physiological conditions and provides a useful tool for imaging oxidative stress in cardiovascular diseases.
- Open Access
- 13 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (61) , e77100
Plaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis
Atherosclerosis remains the leading cause of cardiovascular mortality, with elevated oxidized low‐density lipoprotein (oxLDL) as a key driver. oxLDL metabolism involves two critical steps: generation mediated by proprotein convertase subtilisin/kexin type 9 (PCSK9)‐induced LDLR degradation, and plaque uptake via lectin‐like oxLDL receptor‐1 (LOX‐1). Current PCSK9 inhibitors reduce oxLDL production but show limited effects on plaque oxLDL uptake and inflammation. Thus, synergistic strategies targeting both steps are urgently needed. To address this, we developed a hepatic‐plaque targeting nanoparticle, siPCSK9@PEAL NPs‐aL, based on a PEG‐PLGA‐PLL framework. The nanoparticle was surface‐functionalized with anti‐LOX‐1 antibody for plaque targeting. Concurrently, optimized particle size enabled hepatic accumulation while minimizing clearance by the reticuloendothelial system (RES), facilitating effective hepatic delivery of siPCSK9. The PLGA core allowed controlled siRNA release, and the cationic PLL layer promoted efficient condensation and protection. In vitro, this system effectively silenced PCSK9, downregulated LOX‐1, rescued mitochondrial function and reduced apoptosis. In advanced atherosclerosis mice, weekly administration significantly reduced aortic plaque burden, stabilized plaque composition, and normalized serum lipid levels. Lipidomics showed oxLDL‐associated lipid downregulation and metabolic networks remodeling. Taken together, this dual‐targeting nanodrug integrates systemic lipid‐lowering with local anti‐inflammatory effects by simultaneously inhibiting oxLDL generation and utilization, offering a promising precision therapeutic strategy for atherosclerosis.
- 13 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (61) , e77100
Open AccessPlaque‐Hepatic Targeting Nanotherapy Disrupts the PCSK9‐LOX‐1 Axis to Suppress oxLDL in Atherosclerosis
Atherosclerosis remains the leading cause of cardiovascular mortality, with elevated oxidized low‐density lipoprotein (oxLDL) as a key driver. oxLDL metabolism involves two critical steps: generation mediated by proprotein convertase subtilisin/kexin type 9 (PCSK9)‐induced LDLR degradation, and plaque uptake via lectin‐like oxLDL receptor‐1 (LOX‐1). Current PCSK9 inhibitors reduce oxLDL production but show limited effects on plaque oxLDL uptake and inflammation. Thus, synergistic strategies targeting both steps are urgently needed. To address this, we developed a hepatic‐plaque targeting nanoparticle, siPCSK9@PEAL NPs‐aL, based on a PEG‐PLGA‐PLL framework. The nanoparticle was surface‐functionalized with anti‐LOX‐1 antibody for plaque targeting. Concurrently, optimized particle size enabled hepatic accumulation while minimizing clearance by the reticuloendothelial system (RES), facilitating effective hepatic delivery of siPCSK9. The PLGA core allowed controlled siRNA release, and the cationic PLL layer promoted efficient condensation and protection. In vitro, this system effectively silenced PCSK9, downregulated LOX‐1, rescued mitochondrial function and reduced apoptosis. In advanced atherosclerosis mice, weekly administration significantly reduced aortic plaque burden, stabilized plaque composition, and normalized serum lipid levels. Lipidomics showed oxLDL‐associated lipid downregulation and metabolic networks remodeling. Taken together, this dual‐targeting nanodrug integrates systemic lipid‐lowering with local anti‐inflammatory effects by simultaneously inhibiting oxLDL generation and utilization, offering a promising precision therapeutic strategy for atherosclerosis.
- 23 February 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (9) , 7752-7772
Microenvironment-Triggered Signal Amplification for Dual-Modal Fluorescence/MRI of Hepatocellular Carcinoma
Dual-modal fluorescence/magnetic resonance imaging (FL/MRI) offers sensitive and high-resolution detection of hepatocellular carcinoma (HCC), but its effectiveness is often limited by weak signal synergy and poor responsiveness to the tumor microenvironment. Here, we report a tumor-microenvironment-responsive nanoprobe, TCM-Gd-P NPs, designed to remain initially signal-silent, as amphiphilic polymer encapsulation sequesters the aggregation-induced emission luminogen (TCM-4COOLi) and restricts water interaction with Gd3+ ions, effectively quenching fluorescence and reducing longitudinal relaxivity. Under acidic tumor conditions, protonation of the polymer matrix restricts intramolecular motion of TCM-4COOLi, triggering up to a 12.4-fold fluorescence enhancement at 584 nm, while TCM-4COOGd complexes increase water proton accessibility, producing an ∼8.0-fold increase in longitudinal relaxivity and spatially coupled MRI signal amplification. In vivo, TCM-Gd-P NPs achieved 4.2-fold fluorescence and 3.3-fold MRI contrast enhancement in tumors relative to adjacent tissue, enabling molecular-level delineation of tumor margins via fluorescence imaging and high-resolution anatomical mapping via MRI. Importantly, by applying both modalities to the same orthotopic HCC mice, the high sensitivity of fluorescence imaging effectively corroborated the deep-tissue anatomical resolution provided by MRI. This work establishes a microenvironment-triggered, orthogonal signal amplification strategy for FL/MRI, providing a generalizable framework for intelligent solid-tumor diagnostics.
- 23 February 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (9) , 7752-7772
Microenvironment-Triggered Signal Amplification for Dual-Modal Fluorescence/MRI of Hepatocellular Carcinoma
Dual-modal fluorescence/magnetic resonance imaging (FL/MRI) offers sensitive and high-resolution detection of hepatocellular carcinoma (HCC), but its effectiveness is often limited by weak signal synergy and poor responsiveness to the tumor microenvironment. Here, we report a tumor-microenvironment-responsive nanoprobe, TCM-Gd-P NPs, designed to remain initially signal-silent, as amphiphilic polymer encapsulation sequesters the aggregation-induced emission luminogen (TCM-4COOLi) and restricts water interaction with Gd3+ ions, effectively quenching fluorescence and reducing longitudinal relaxivity. Under acidic tumor conditions, protonation of the polymer matrix restricts intramolecular motion of TCM-4COOLi, triggering up to a 12.4-fold fluorescence enhancement at 584 nm, while TCM-4COOGd complexes increase water proton accessibility, producing an ∼8.0-fold increase in longitudinal relaxivity and spatially coupled MRI signal amplification. In vivo, TCM-Gd-P NPs achieved 4.2-fold fluorescence and 3.3-fold MRI contrast enhancement in tumors relative to adjacent tissue, enabling molecular-level delineation of tumor margins via fluorescence imaging and high-resolution anatomical mapping via MRI. Importantly, by applying both modalities to the same orthotopic HCC mice, the high sensitivity of fluorescence imaging effectively corroborated the deep-tissue anatomical resolution provided by MRI. This work establishes a microenvironment-triggered, orthogonal signal amplification strategy for FL/MRI, providing a generalizable framework for intelligent solid-tumor diagnostics.
- 1 February 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (15) , e04898
Triple‐Targeting Cascade Nanoplatform Enhances Tumor Stromal Permeation with Intracellular Accumulation
Nano‐based drug delivery systems often encounter challenges in insufficient tumor cell internalization, particularly in deep cells, due to dense tumor stroma, which limits drug delivery efficiency and antitumor efficacy. Here we present a smart nanoplatform (Trans‐btND) with an onion‐like multilayered structure, comprising a negatively charged heparin outer layer, a hyaluronidase (HAase) sublayer, and a positively charged reactive oxygen species (ROS)‐responsive drug‐loaded core. This design enables a triple‐targeting strategy for effective tumor cell internalization: (i) heparin‐mediated active targeting, driven by the affinity between heparin and overexpressed heparanase, promotes Trans‐btND accumulation at tumor sites; (ii) charge‐reversal‐triggered tumor cell targeting, induced by the sequential degradation of heparin and HAase layers, facilitates cellular uptake via electrostatic interactions; (iii) ROS‐activatable targeting, initiated by elevated intracellular ROS levels, enables precise cytosolic drug release. Notably, during the process, Trans‐btND undergoes stepwise size reduction, intracellular transcytosis, and HAase‐mediated stromal degradation, thereby promoting deeper tumor penetration. Therefore, Trans‐btND with enhanced tumor targeting and stroma penetration can significantly augment delivery efficiency and amplify antitumor potency, providing a promising strategy for cancer therapy.
- 1 February 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (15) , e04898
Triple‐Targeting Cascade Nanoplatform Enhances Tumor Stromal Permeation with Intracellular Accumulation
Nano‐based drug delivery systems often encounter challenges in insufficient tumor cell internalization, particularly in deep cells, due to dense tumor stroma, which limits drug delivery efficiency and antitumor efficacy. Here we present a smart nanoplatform (Trans‐btND) with an onion‐like multilayered structure, comprising a negatively charged heparin outer layer, a hyaluronidase (HAase) sublayer, and a positively charged reactive oxygen species (ROS)‐responsive drug‐loaded core. This design enables a triple‐targeting strategy for effective tumor cell internalization: (i) heparin‐mediated active targeting, driven by the affinity between heparin and overexpressed heparanase, promotes Trans‐btND accumulation at tumor sites; (ii) charge‐reversal‐triggered tumor cell targeting, induced by the sequential degradation of heparin and HAase layers, facilitates cellular uptake via electrostatic interactions; (iii) ROS‐activatable targeting, initiated by elevated intracellular ROS levels, enables precise cytosolic drug release. Notably, during the process, Trans‐btND undergoes stepwise size reduction, intracellular transcytosis, and HAase‐mediated stromal degradation, thereby promoting deeper tumor penetration. Therefore, Trans‐btND with enhanced tumor targeting and stroma penetration can significantly augment delivery efficiency and amplify antitumor potency, providing a promising strategy for cancer therapy.
- 15 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123633
Temperature-activated in situ hydrogel augments tumor treatment
- 15 August 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123633
Temperature-activated in situ hydrogel augments tumor treatment
- 19 March 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (12) , 12119-12137
Electrostatically Stabilized Light-Activated Membrane Delivery System: Overcoming Membrane Flexibility and Self-Repair to Enhance Tumor Therapy
Cell membrane-coated nanoparticle-based delivery systems often struggle with inevitable drug leakage during the delivery process and inefficient drug release at the tumor site, resulting in unsatisfactory antitumor outcomes. Here, we present an electrostatically stabilized light-activated membrane delivery system (Hybrid membrane nanoparticles, [Hm]@NPs) for leak-free drug delivery, coupled with precisely site-specific and controllable drug release, to elevate cancer treatment. [Hm]@NPs are constructed by encapsulating an aggregation-induced emission (AIE) photosensitizer (Phenalen-1-one-quinoline malonitrile-thiophene tribenamine, Phe-Qui-T) into a positively charged reactive oxygen species (ROS)-responsive polymer (F127-TP-U11) to form a positively charged nanoparticle and then coating it with a negatively charged hybrid membrane containing red blood cell membrane and Panc-1 cell membrane. [Hm]@NPs with high stability effectively prevent drug leakage through electrostatic interaction between the hybrid membrane and nanoparticle. Simultaneously, the photosensitizer Phe-Qui-T with light-controlled ROS generation efficiently destroys both the ROS-responsive polymer and the hybrid membrane, ensuring precise and sufficient drug release while enabling photodynamic therapy (PDT), thereby augmenting antitumor efficacy. [Hm]@NPs show impressive tumor inhibition in pancreatic cancer mouse models, highlighting the potential of this light-controlled membrane-disruption strategy for advanced cell membrane-coated nanodelivery system design.
- 19 March 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (12) , 12119-12137
Electrostatically Stabilized Light-Activated Membrane Delivery System: Overcoming Membrane Flexibility and Self-Repair to Enhance Tumor Therapy
Cell membrane-coated nanoparticle-based delivery systems often struggle with inevitable drug leakage during the delivery process and inefficient drug release at the tumor site, resulting in unsatisfactory antitumor outcomes. Here, we present an electrostatically stabilized light-activated membrane delivery system (Hybrid membrane nanoparticles, [Hm]@NPs) for leak-free drug delivery, coupled with precisely site-specific and controllable drug release, to elevate cancer treatment. [Hm]@NPs are constructed by encapsulating an aggregation-induced emission (AIE) photosensitizer (Phenalen-1-one-quinoline malonitrile-thiophene tribenamine, Phe-Qui-T) into a positively charged reactive oxygen species (ROS)-responsive polymer (F127-TP-U11) to form a positively charged nanoparticle and then coating it with a negatively charged hybrid membrane containing red blood cell membrane and Panc-1 cell membrane. [Hm]@NPs with high stability effectively prevent drug leakage through electrostatic interaction between the hybrid membrane and nanoparticle. Simultaneously, the photosensitizer Phe-Qui-T with light-controlled ROS generation efficiently destroys both the ROS-responsive polymer and the hybrid membrane, ensuring precise and sufficient drug release while enabling photodynamic therapy (PDT), thereby augmenting antitumor efficacy. [Hm]@NPs show impressive tumor inhibition in pancreatic cancer mouse models, highlighting the potential of this light-controlled membrane-disruption strategy for advanced cell membrane-coated nanodelivery system design.
- Open Access
- 4 September 2024
- Published by Wiley in Smart Molecules
- Vol. 3 (2)
An azo substituted quinoline‐malononitrile enzyme‐activable aggregation‐induced emission nanoprobe for hypoxia imaging
The development of efficient aggregation‐induced emission (AIE) active probes is crucial for disease diagnosis, particularly for tumors and cardiovascular diseases. Current AIE‐active probes primarily focus on improving their water solubility to resist aggregation, thereby achieving an initial fluorescence‐off state. However, the complex biological environment can cause undesirable aggregation, resulting in false signals. To address this issue, we have ingeniously introduced an azo group into the AIE luminogen (AIEgen), developing a reductase‐activated AIE probe, Azo‐quinoline‐malononitrile (QM)‐PN, for imaging hypoxic environments. In this probe, the azo group promotes intramolecular motion through rapid E/Z isomerization, causing the excited state energy to dissipate via non‐radiative decay, thus turning off the initial fluorescence. In the presence of reductase, Azo‐QM‐PN is reduced and cleaved to produce the hydrophobic AIEgen NH2‐QM‐PN, which subsequently aggregates and generates an in situ AIE signal, thereby imaging the hypoxic environment with reductase. Encapsulation of Azo‐QM‐PN with DSPE‐PEG2000 results in the formation of the nanoprobe Azo‐QM‐PN NPs, which can effectively penetrate cell membranes, specifically illuminate tumor cells, monitor fluctuations in azo reductase levels, and deeply penetrate and image multicellular tumor spheroids, demonstrating potential for hypoxic tumor imaging. Additionally, the nanoprobe Azo‐QM‐PN NPs can selectively image hypoxic atherosclerotic plaque tissues, showing potential for detecting atherosclerosis. Therefore, in this study, we successfully developed an enzyme‐activated AIE probe for imaging hypoxic environments, laying the foundation for further clinical applications.
- 4 September 2024
- Published by Wiley in Smart Molecules
- Vol. 3 (2)
Open AccessAn azo substituted quinoline‐malononitrile enzyme‐activable aggregation‐induced emission nanoprobe for hypoxia imaging
The development of efficient aggregation‐induced emission (AIE) active probes is crucial for disease diagnosis, particularly for tumors and cardiovascular diseases. Current AIE‐active probes primarily focus on improving their water solubility to resist aggregation, thereby achieving an initial fluorescence‐off state. However, the complex biological environment can cause undesirable aggregation, resulting in false signals. To address this issue, we have ingeniously introduced an azo group into the AIE luminogen (AIEgen), developing a reductase‐activated AIE probe, Azo‐quinoline‐malononitrile (QM)‐PN, for imaging hypoxic environments. In this probe, the azo group promotes intramolecular motion through rapid E/Z isomerization, causing the excited state energy to dissipate via non‐radiative decay, thus turning off the initial fluorescence. In the presence of reductase, Azo‐QM‐PN is reduced and cleaved to produce the hydrophobic AIEgen NH2‐QM‐PN, which subsequently aggregates and generates an in situ AIE signal, thereby imaging the hypoxic environment with reductase. Encapsulation of Azo‐QM‐PN with DSPE‐PEG2000 results in the formation of the nanoprobe Azo‐QM‐PN NPs, which can effectively penetrate cell membranes, specifically illuminate tumor cells, monitor fluctuations in azo reductase levels, and deeply penetrate and image multicellular tumor spheroids, demonstrating potential for hypoxic tumor imaging. Additionally, the nanoprobe Azo‐QM‐PN NPs can selectively image hypoxic atherosclerotic plaque tissues, showing potential for detecting atherosclerosis. Therefore, in this study, we successfully developed an enzyme‐activated AIE probe for imaging hypoxic environments, laying the foundation for further clinical applications.
- Open Access
- 29 August 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (38) , 15647-15658
Cascade-responsive size/charge bidirectional-tunable nanodelivery penetrates pancreatic tumor barriers
A cascade-responsive nanodelivery (btND, G/R@TKP/HA) with size/charge bidirectional-tunability could navigate through almost all pancreatic tumor delivery obstacles simultaneously, thereby augmenting the drug delivery depth and anticancer efficacy.
- 29 August 2024
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 15 (38) , 15647-15658
Open AccessCascade-responsive size/charge bidirectional-tunable nanodelivery penetrates pancreatic tumor barriers
A cascade-responsive nanodelivery (btND, G/R@TKP/HA) with size/charge bidirectional-tunability could navigate through almost all pancreatic tumor delivery obstacles simultaneously, thereby augmenting the drug delivery depth and anticancer efficacy.